Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.54 |
| ▸ | MAPT | P10636 | 6/20 | 0.54 |
| ▸ | MEN1 | O00255 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | SERPINE1 | P05121 | 6/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | THRB | P10828 | 3/20 | 0.39 |
| ▸ | RECQL | P46063 | 3/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 2/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | PHPT1 | Q9NRX4 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2114176 | 1.00 | ALDH1A1 (0.54) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL2113128 | 0.83 | MEN1 (0.60) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL2112670 | 0.81 | MEN1 (0.67) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL2112673 | 0.81 | MEN1 (0.67) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL2113567 | 0.81 | KDM4E (0.56) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL2113902 | 0.80 | MAPT (0.54) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL2114186 | 0.79 | ALDH1A1 (0.56) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL2111333 | 0.79 | MAPT (0.55) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL2111335 | 0.79 | MAPT (0.55) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL2114548 | 0.79 | MEN1 (0.55) | ALDH1A1KDM4EMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158623-B2 | Heptacyclic compounds and the pharmaceutical uses thereof for preventing and treating diabetes and metabolic syndrome | SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) | 2012-04-17 | — | — | US | disclosed |
| US-20100173905-A1 | HEPTACYCLIC COMPOUNDS AND THE PHARMACEUTICAL USES THEREOF FOR PREVENTING AND TREATING DIABETES AND METABOLIC SYNDROME | SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCE | 2010-07-08 | — | — | US | disclosed |
| EP-2199295-A1 | COMPOUNDS WITH 7-MEMBER CYCLE AND THE PHARMACEUTICAL USE THEREOF FOR PREVENTING AND TREATING DIABETES AND METABOLISM SYNDROME | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2010-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173905-A1 | HEPTACYCLIC COMPOUNDS AND THE PHARMACEUTICAL USES THEREOF FOR PREVENTING AND TREATING DIABETES AND METABOLIC SYNDROME | GPR119, CYP11B1, HSD11B1 | ALDH1A1 1503/4885KDM4E 4346/4885MAPT 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.